Inve US ▾
NVNVST

Envista Holdings (NVST) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Envista Holdings Q2 FY26 — Strong Core Growth and Raised Full-Year Guidance

Envista Holdings delivered a robust second quarter, marked by broad-based core revenue growth and significant margin expansion, driven by operational efficiencies and new product innovation. The company raised its full-year guidance, reflecting confidence in its execution and the dental market's resilience, despite anticipated price compression from China's VBP initiatives in the second half. Management continues to focus on strategic investments in R&D and sales to sustain future growth.

Highlights

5

  • Core growth of 5% in Q2 FY26, with balanced performance across segments and geographies.

  • Adjusted EBITDA increased 28% year-over-year, with margin expansion of 230 basis points to 14.7%.

  • Adjusted EPS grew 58% year-over-year to $0.41.

  • Free cash flow conversion was strong at 158% in Q2 FY26.

  • Full-year 2026 guidance raised for core growth (3.5%-4.5%), adjusted EBITDA (11%-14%), and adjusted EPS ($1.50-$1.55).

Concerns

3

  • Brackets and wires segment was down high single digits in Q2 FY26 due to a strong prior-year comparable.

  • Q4 FY26 core growth expected to be flat to slightly down due to 4 fewer selling days.

  • China VBP 1 for ortho and VBP 2 for implants expected to result in significant price compression in the second half of FY26.

Guidance & targets

CategoryTargetConfidence
Full-year 2026 Core Growth
3.5% to 4.5%
high materiality
High
Full-year 2026 Adjusted EBITDA Growth
11% to 14%
high materiality
High
Full-year 2026 Adjusted EPS
$1.50 to $1.55
high materiality
High
Full-year 2026 Free Cash Flow Conversion
approximately 100%
medium materiality
High
Full-year 2026 Non-GAAP Tax Rate
around 26%
medium materiality
High
Q4 FY26 Core Growth
flat to slightly down
medium materiality
High
Q3 & Q4 FY26 Adjusted EBITDA Growth
roughly in line with sales growth
medium materiality
High

Segment performance

SegmentRevenueYoYQoQMargin
Equipment & Consumables
Consumables business continues to deliver well across the portfolio, driven by innovation and good price performance. Diagnostics particularly strong in North America, posting above-market growth. Consistent innovation in equipment and software combined with growth in services to meet customer needs for comprehensive solutions.
Diagnostics growth: high single digitsConsumables growth: high single digits
—8.5%—250 bps improvement in operating margins
Specialty Products & Technologies
Spark again delivered double-digit growth. Brackets and wires was down against a strong Q2 2025 comparable. Implant core growth consistent with recent quarters and well balanced across geographic markets. Both businesses had positive price capture.
Spark growth: double digits (high single digits after adjusting for net deferral change)Implants core growth: low single digitsBrackets and wires growth: down high single digits
—3.1%—120 bps improvement in margin rate

Product announcements

ProductTypeDetails
ZenSeal Prolaunch
DemiProlaunch
Ormco Digital Bonding (ODB)expansion

Deals & partnerships

Versah Acquisition of osseodensification technology

Acquired osseodensification technology, which had already been developed and gained registration in many markets. Envista's strategy is to commercialize it globally through its worldwide presence. The acquisition is running ahead of plan.

Risks & headwinds

China VBP Price Compression H2 FY26

Ortho VBP 1: around 45% price compression; Implants VBP 2: 10-15% price compression

Mitigation:Expected volume increases and market share gains post-VBP, leveraging a well-prepared channel and strong global brand position.

Selling Day Impact on Q4 Revenue Q4 FY26

Q4 FY26 core growth expected to be flat to slightly down

Mitigation:The underlying business growth, normalized for the 4 fewer selling days, is expected to be in line with the full-year guidance range, indicating consistent performance.

Macroeconomic Uncertainty Ongoing

Impacts more elective categories like implants and orthodontics

Mitigation:Diversified portfolio with strong positions in less sensitive categories (consumables, diagnostics) and across major geographies (Europe, APAC, Latin America) helps offset volatility. Anticipates tailwind as consumer confidence rebuilds.

Tariff Costs H2 FY26

$5M increase in Q2 FY26 vs Q2 FY25; expected to be similar in H2 FY26

Mitigation:Offsetting costs through supply chain, G&A, and pricing actions. Recently announced Section 301 levies effectively replace prior tariffs.

What to watch in Q3 FY26

China VBP impact on ortho and implants

H2 FY26
Current Ortho VBP 1 price compression ~45%, Implants VBP 2 price compression 10-15%
Target Volume increases and market share gains offsetting price compression

Why it matters

Determines net financial impact and market positioning in a key growth region.

With respect to China VBP, our revised guidance assumes both VBP 1 for ortho and VBP 2 for implants to take place in the second half.

Find out whether NVST delivers this. Inve re-checks your case every morning.

Q&A highlights

Is the consistent high-single-digit/low-double-digit growth in the E&C segment driven by market upturns or Envista-specific factors like share gains and new products?

Paul Keel attributed the growth to market tailwinds (consumables insulated, diagnostics market recovery), Envista's share gains driven by new products, and the benefit of a balanced portfolio offsetting macro volatility in elective categories. Eric Hammes confirmed the comprehensive answer.

“Our E&C segment is delivering consistently faster growth. And I think I would point to at least 3 contributors that are supporting the trend.”

asked by Jon Block · answered by Paul Keel

2 min read 6 chapters

Detailed narrative

Operational Excellence and Margin Expansion

Envista Business System (EBS) continues to drive widespread benefits, improving manufacturing productivity and G&A efficiency. This led to a 70 basis point gross margin expansion and 230 basis point adjusted EBITDA margin expansion in Q2. The company also reduced its effective tax rate to 25% in Q2, contributing to strong EPS growth. Management noted that the bigger opportunity for margin improvement lies in COGS productivity, with several programs underway.

New Product Innovation Driving Growth

New product launches are playing a central role in Envista's growth strategy. In consumables, ZenSeal Pro, a bioceramic endodontic sealer, and DemiPro, a lightweight cordless curing light, were launched. In orthodontics, Ormco Digital Bonding (ODB) was expanded to cover all bracket systems, leveraging digital capabilities for fixed orthodontics. These innovations are expected to build on consistent share gains in consumables and orthodontics, reflecting increased investments in new product development and commercialization over the last two years.

China VBP Strategy and Outlook

Envista anticipates China VBP 1 for orthodontics and VBP 2 for implants to take place in H2 FY26. While VBP 1 for ortho is expected to result in significant price compression (around 45%), it is also projected to lead to market share gains and volume increases, similar to the first implant VBP. VBP 2 for implants is expected to have smaller price compression (10-15%) with volume growth primarily driven by market share. The company maintains a long-term commitment to the Chinese market, expecting it to become the largest dental market globally.

Implants Business Performance and Investment

The implants business achieved low single-digit core growth in Q2, consistent with market trends and balanced across geographies and product categories. Contributions from regenerative biomaterials and digital workflow were strong. Recent investments in new product development, such as the S series launch, are yielding positive results, with the S series exceeding launch plans and driving competitive conversion. The acquisition of Versah, an osseodensification technology, is also performing ahead of expectations.

Balanced Portfolio and Geographic Diversification

Envista's portfolio benefits from diversification across elective categories like implants and orthodontics, and less sensitive categories such as consumables and diagnostics. This balance helps offset macro uncertainties. Geographically, strong performance in Europe, APAC, and Latin America helps mitigate a softer North American market. The company expects to benefit from a helpful tailwind as consumer confidence rebuilds in North America and the dental market rebounds.

Capital Allocation and Shareholder Returns

The company maintains a strong and stable balance sheet with a net debt to adjusted EBITDA ratio of 0.7x, providing flexibility amidst macroeconomic uncertainty. In Q2, Envista continued to return cash to shareholders, purchasing approximately 2.4 million shares of its stock at an average price of $24 per share. This reflects a commitment to shareholder value while also investing for future growth.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.